DOC vs GMRE Stock Comparison
Compare DOC and GMRE across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between DOC and GMRE?
GMRE leads the current stock comparison as Global Medical REIT Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Healthpeak Properties, Inc. vs Global Medical REIT Inc.
GMRE leads
GMRE leads by 16 AIQ points, primarily on Value and Quality, and the lead has widened from 8 points over 30 sessions.
Stable: 5 of 6 evidence groups support GMRE, and its lead is widening.
Healthpeak Properties, Inc.
Global Medical REIT Inc.
The Algovestiq AIQ Score currently favors GMRE over DOC, 50 versus 34 as of Sep 11, 2026. GMRE's advantage is driven primarily by stronger value and quality. GMRE also shows the stronger technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor GMRE today, and the comparison is rated Stable on stability. GMRE lead: Strengthening — the AIQ differential moved from 8 to 16 points over 30 sessions.
Compare Healthpeak Properties, Inc. and Global Medical REIT Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare DOC and GMRE against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value35 vs 60GMRE +25
- Quality15 vs 26GMRE +11
- Risk Resilience76 vs 78Even
5 of 6 evidence groups favor GMRE. GMRE’s edge is concentrated in value and quality.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -10
No new signals fired.
No factor moved materially.
No new signals fired.
GMRE's lead widened by 3 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — DOC and GMRE both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
GMREGMRE on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
GMREGMRE on combined revenue and EPS growth.
Value
GMREGMRE on the peer-relative Value factor, by 25 points.
Momentum
EvenThe two are level on Momentum.
Lower downside
DOCDOC carries the lower 1-month annualized volatility.
Analyst upside
GMREGMRE on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | DOC | GMRE | Note |
|---|---|---|---|
| Implied upside to target | +5.5% | +11.9% | GMRE has more room |
| Target dispersion | +32.7% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 8 | 1 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor GMRE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | GMRE | 34 vs 50 |
| Fundamentals | GMREon balance | revenue growth 2.5% vs 4.4%; EPS growth -71.4% vs 80.8%; TTM ROE 3.3% vs 10.8%; gross margin 2.5% vs 0.4%; operating margin 17.6% vs 25.5% — GMRE takes 4 of 5 decided legs, not all of them |
| Valuation | GMRE | Value 35 vs 60 |
| Technicals | GMRE | Price vs 50-day -5.5% vs 1.7%; vs 200-day 9.2% vs 5.5% |
| Risk Resilience | Even | Risk Resilience 76 vs 78 |
| Analyst expectations | GMRE | Target upside 5.5% vs 11.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of DOC and GMRE and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 16 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on GMRE.
How the comparison changed
119 daily snapshots · May 4 – Sep 10GMRE lead: Strengthening — the AIQ differential moved from 8 to 16 points over 30 sessions.
- Today
- GMRE +16
- 34 vs 50
- 7 sessions ago
- GMRE +12
- 38 vs 50
- 30 sessions ago
- GMRE +8
- 40 vs 48
- 90 sessions ago
- DOC +2
- 50 vs 48
The lead changed hands 5 times in this window, most recently on Aug 27 when GMRE moved ahead of DOC.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 1 bearish / 1 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (15.09%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
No active signals
DOC is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -0.34%, AIQ -3 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1DOC closes the Value gap — currently 25 points behind, the largest single contributor to GMRE's edge.
- 2DOC's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it.
- 3GMRE starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
GMRE leads on balance| Metric | DOC | GMRE |
|---|---|---|
| Revenue growth (YoY) | 2.5% | 4.4% |
| EPS growth (YoY) | -71.4% | 80.8% |
| Gross margin | 2.5% | 0.4% |
| Operating margin | 17.6% | 25.5% |
| Return on equity (TTM) | 3.3% | 10.8% |
| Debt to equity | 1.32 | 0.97 |
Performance
Split across windows| Metric | DOC | GMRE |
|---|---|---|
| 1 week (5 sessions) | -3.1% | -0.5% |
| 1 month (20 sessions) | -1.4% | 1.4% |
| 3 months (63 sessions) | -0.5% | 11.1% |
| 6 months (126 sessions) | 19.3% | 2.1% |
| Year to date | 26.7% | 6.6% |
| 1 year (252 sessions) | 11.3% | -13.7% |
Technicals
GMRE has the stronger structure| Metric | DOC | GMRE |
|---|---|---|
| RSI (14) | 30.9 | 65.4 |
| ADX (14) | 16.7 | 25.5 |
| Price vs 50-day | -5.5% | 1.7% |
| Price vs 200-day | 9.2% | 5.5% |
| Volatility (1M, annualized) | 16.7% | 20.6% |
Risk
Split| Metric | DOC | GMRE |
|---|---|---|
| Beta | 0.42 | 0.04 |
| Sharpe ratio | 0.42 | 0.66 |
| Sortino ratio | 0.81 | 0.96 |
| Max drawdown | -18.5% | -22% |
| Current drawdown | -10.7% | -6.9% |
| Annualized volatility | 28.9% | 29.1% |
| Value at risk (95%) | -2.3% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, DOC or GMRE?
On the Algovestiq AIQ Score, GMRE is the stronger of the two as of Sep 11, 2026, scoring 50 against DOC's 34. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is DOC or GMRE the better buy right now?
GMRE carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor GMRE over DOC?
The composite weights Quality, Value, Momentum and Risk Resilience. GMRE leads Value by 25 points; GMRE leads Quality by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, DOC or GMRE?
Analyst price targets imply +5.5% upside for DOC and +11.9% for GMRE, so the Street currently favors GMRE. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, DOC or GMRE?
GMRE is the better-valued of the two on the peer-relative Value factor. GMRE on the peer-relative Value factor, by 25 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, DOC or GMRE?
GMRE on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, DOC or GMRE?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, DOC or GMRE?
DOC is the more resilient of the two, so the other name carries the higher downside risk. DOC carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is DOC more profitable than GMRE?
The profitability evidence is mixed: gross margin 2.5% vs 0.4%; operating margin 17.6% vs 25.5%; ttm roe 3.3% vs 10.8%. DOC leads on one measure and GMRE on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is GMRE's lead over DOC getting stronger or weaker?
GMRE lead: Strengthening — the AIQ differential moved from 8 to 16 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 5 times in that window, most recently on 2026-08-27, when GMRE moved ahead of DOC.
What would change the DOC vs GMRE verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: DOC closes the Value gap — currently 25 points behind, the largest single contributor to GMRE's edge; DOC's MACD Bearish Crossover resolves — a bearish momentum rule currently active against it; GMRE starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about DOC and GMRE?
DOC: 1 bullish / 1 bearish / 1 neutral, conflicted. GMRE: No active signals. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on DOC is Golden Cross Active (bullish, long horizon).
Compare DOC and GMRE with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.